JP2022550899A5 - - Google Patents

Info

Publication number
JP2022550899A5
JP2022550899A5 JP2022520797A JP2022520797A JP2022550899A5 JP 2022550899 A5 JP2022550899 A5 JP 2022550899A5 JP 2022520797 A JP2022520797 A JP 2022520797A JP 2022520797 A JP2022520797 A JP 2022520797A JP 2022550899 A5 JP2022550899 A5 JP 2022550899A5
Authority
JP
Japan
Prior art keywords
cells
receptor
derived
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550899A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054601 external-priority patent/WO2021071962A1/en
Publication of JP2022550899A publication Critical patent/JP2022550899A/ja
Publication of JP2022550899A5 publication Critical patent/JP2022550899A5/ja
Pending legal-status Critical Current

Links

JP2022520797A 2019-10-07 2020-10-07 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 Pending JP2022550899A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962912000P 2019-10-07 2019-10-07
US62/912,000 2019-10-07
US201962916468P 2019-10-17 2019-10-17
US62/916,468 2019-10-17
PCT/US2020/054601 WO2021071962A1 (en) 2019-10-07 2020-10-07 Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof

Publications (2)

Publication Number Publication Date
JP2022550899A JP2022550899A (ja) 2022-12-05
JP2022550899A5 true JP2022550899A5 (OSRAM) 2023-10-17

Family

ID=75437509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520797A Pending JP2022550899A (ja) 2019-10-07 2020-10-07 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Country Status (11)

Country Link
US (1) US20240115602A1 (OSRAM)
EP (1) EP4041759A4 (OSRAM)
JP (1) JP2022550899A (OSRAM)
KR (1) KR20220108038A (OSRAM)
CN (1) CN114761425A (OSRAM)
AU (1) AU2020363697A1 (OSRAM)
BR (1) BR112022006440A2 (OSRAM)
CA (1) CA3151781A1 (OSRAM)
IL (1) IL291924A (OSRAM)
MX (1) MX2022004080A (OSRAM)
WO (1) WO2021071962A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121505B (zh) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 嵌合抗原受体和表达其的自然杀伤细胞
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
EP3712178A4 (en) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
WO2023129937A1 (en) * 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
KR20250005097A (ko) 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
JP7707304B2 (ja) 2022-04-08 2025-07-14 フェイト セラピューティクス，インコーポレイティド 腫瘍標的化のためのキメラ抗原受容体
WO2023215278A1 (en) * 2022-05-03 2023-11-09 The Broad Institute, Inc. Modified immune cells and methods for use thereof
JP2025516571A (ja) * 2022-05-10 2025-05-30 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫寛容を増強するための組成物及び方法
US20250090582A1 (en) * 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CN119816313A (zh) * 2022-08-17 2025-04-11 埃迪瓦生物治疗公司 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法
WO2024140778A1 (zh) * 2022-12-27 2024-07-04 科济生物医药（上海）有限公司 Nkg2d工程化细胞及其组合物
WO2024159219A2 (en) * 2023-01-29 2024-08-02 Case Western Reserve University Chimeric antigen receptor constructs with optimized intracellular domains for natural killer cells
CN117285651B (zh) * 2023-09-27 2025-06-06 中国医学科学院北京协和医院 靶向c-MET的嵌合抗原受体、CAR-M及其用途
AU2024287298A1 (en) * 2023-09-28 2025-04-17 PELL Bio-Med Technology Co., Ltd. Nucleic acid molecule comprising intracellular signaling domain and nkp30 transmembrane domain and chimeric antigen receptor comprising the same
WO2025097150A1 (en) * 2023-11-03 2025-05-08 The University Of Chicago Bcl-2 inhibition to amplify chimeric antigen receptor therapy
CN118420786B (zh) * 2024-06-12 2025-10-17 浙江大学医学院附属第一医院(浙江省第一医院) 一种靶向her2和hla-g的双特异性嵌合抗原受体及其应用
CN121227639A (zh) * 2024-06-28 2025-12-30 上海苹谱医疗科技有限公司 具有增强肿瘤靶向浸润能力的间充质干细胞及其应用
WO2026067758A1 (en) * 2024-09-29 2026-04-02 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
JP6849600B6 (ja) * 2015-01-29 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ キメラ抗原受容体、組成物及び方法
WO2017078807A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN108368520B (zh) * 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
AU2017301826A1 (en) * 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
WO2018118494A2 (en) * 2016-12-22 2018-06-28 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
WO2018132506A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
EP3697809A1 (en) * 2017-10-20 2020-08-26 Institut Curie Dap10/12 based cars adapted for rush
AU2018355462B9 (en) * 2017-10-26 2022-04-28 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
BR112020010597A2 (pt) * 2017-12-08 2020-10-27 Fate Therapeutics, Inc. imunoterapias com o uso de células efetoras derivadas de ipsc intensificadas
KR20250048610A (ko) * 2017-12-22 2025-04-09 페이트 세러퓨틱스, 인코포레이티드 향상된 면역 효과기 세포 및 이의 용도
WO2019173636A1 (en) * 2018-03-07 2019-09-12 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use
WO2019191495A1 (en) * 2018-03-29 2019-10-03 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof

Similar Documents

Publication Publication Date Title
JP2022541441A5 (OSRAM)
JP2022548943A5 (OSRAM)
JP2021505131A5 (OSRAM)
JP2022510207A5 (OSRAM)
US20240141041A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
JP2021519061A5 (OSRAM)
JP2023505206A5 (OSRAM)
JP2023530704A5 (OSRAM)
Bollino et al. Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy
JP2023548467A5 (OSRAM)
JP2022109953A (ja) 細胞免疫療法のための方法および組成物
JP2022552314A5 (OSRAM)
JP2023548829A5 (OSRAM)
EP4148125A1 (en) Engineered immune cell for allotransplantation
JP2023545992A5 (OSRAM)
US10941202B2 (en) Isolated human mesenchymal stem cell expressing a bispecific antibody that binds CD33 and CD3 and method of using to treat cancer
CN114761425A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
RS62870B1 (sr) Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
JP2024533375A5 (OSRAM)
KR20210018838A (ko) 유전자 조작된 세포 및 응용
KR20230137923A (ko) 신규한 키메라 항원 수용체 및 이의 용도
JP2024525492A5 (OSRAM)
AU2021338819A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
JP2024515920A5 (OSRAM)
JP2024536859A5 (OSRAM)